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Abstract Human erythrocytes release neokyotorphin, the 137-
141 fragment of hemoglobin a-chain into the supernatant of red 
blood cells primary culture. However, the neokyotorphin 
fragment 1-4 that is formed together with neokyotorphin inside 
the red blood cells and in various tissues is not found in the 
supernatant. Both neokyotorphin and its 1^4 fragment were 
shown to stimulate proliferation of L929 tumor cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Neokyotorphin (NKT) is a well-studied biologically active 
peptide. This peptide is active in a number of biological tests, 
in particular, N K T exhibits naloxone-dependent analgesic ac-
tivity [1], regulates hibernation [2] and increases potential-de-
pendent Ca 2 + current of frog cardiocytes [3]. 
Both neokyotorphin (NKT) and des-Arg-neokyotorphin 
(des-Arg-NKT, N K T (1^1)) were identified earlier in lung, 
heart and brain tissues [1,2,4] as well as in the erythrocyte 
lysate [5]. The content of N K T in erythrocytes is significantly 
lower than in lung (7-fold) and heart (2-fold) tissues and is 
comparable with the content in brain extracts, while the level 
of des-Arg-NKT in the above mentioned extracts was similar 
to that in erythrocyte lysate [4]. NKT/des-Arg-NKT ratio dif-
fered significantly in the examined tissues (from 113:1 in heart 
to 16:1 in lung), being 1:1 in the erythrocyte lysate [4]. The 
differences in NKT/des-Arg-NKT ratio allowed to suggest 
that accumulation and proteolysis of N K T in tissues could 
be of functional significance in vivo. Bearing in mind that 
des-Arg-NKT shows cytolytic activity in tumor cell lines, 
that N K T itself is inactive in the same test system [4] and 
that N K T was detected in human carcinoma tissue [6] we 
assumed that these peptides could participate in regulation 
of tumor development. Therefore we studied the release of 
N K T and des-Arg-NKT from the erythrocytes and the influ-
ence of both peptides on proliferation of tumor cells. 
2. Materials and methods 
2.1. Peptide synthesis 
Synthesis of NKT and des-Arg-NKT was carried out as described 
in [2]. 
2.2. Preparation of human erythrocytes 
Peripheral venous blood of healthy volunteers was obtained from 
10 healthy volunteers by venipuncture after confirmation of their 
health status by Research Hematological Centre, Russian Academy 
of Medical Sciences. 
Blood samples (25 ml) were placed into the tubes containing citrate 
buffer (to final citrate concentration of 0.25%). The cells were sepa-
rated from plasma by centrifugation at 1000 rpm for 15 min at 0°C. 
The obtained pellet (10-12 millions of cells, 99% of erythrocytes) was 
washed four times by PBS (0.025 M NaH2P04 containing 0.1 M 
NaCl, pH 7.2). 
2.3. Supernatant of the primary culture of erythrocytes 
Five ml of washed cells were incubated with 20 ml of PBS (2.5 X 109 
cells/ml) in culture flacks for 80 min at 37°C. After 20, 40 and 80 min 
of incubation, 8 ml of cell culture medium were centrifuged in con-
ditions described above. The obtained supernatants were lyophilised. 
2.3.1. RP-HPLC separation. The lyophilisates were dissolved in 
250 (il of 0.1%. solution of TFA in water and subjected to separation 
on Nucleosil 120/7^ Ci8 column (10.0X250 mm) (Masherey-Nagel, 
Germany), equilibrated with buffer A (0.1 % TFA in water). The elu-
tion was performed for 50 min by linear gradient of acetonitrile from 
0 to 30% of buffer B (0.1% TFA, 80% acetonitrile solution in water) at 
2.0 ml/min. The detection was carried out at 226 nm. Absorption 
range is given in mV (1800 mV = 2.56 AU). Reproducibility of the 
elution profiles was examined in 7 experiments. Standard deviations 
are given in Fig. 2. 
2.4. Amino acid sequences 
Amino acid sequences of isolated peptides were determined in the 
gas-phase sequencer Applied Biosystems 447A (Foster City, USA). 
Estimation of the peptide content was made from the sequencing 
data. 
2.5. Cell culturing 
L929 cells (transformed murine fibroblasts) were cultured as de-
scribed in [4], Briefly, the cells were generated in DMEM medium 
enriched with 10% foetal calf serum (Gibco BRL) and supplemented 
with 2 mM of glutamine, 100 U/ml of penicillin and 100 mg/ml of 
streptomycin (Gibco BRL). 
2.6. Proliferation assay 
L929 cells (5X 104/well) were placed into 96 well plates (Flow Lab.) 
and co-incubated with 100 ml of culture medium containing different 
concentrations of test substances. The peptides were added to the 
target cells at the beginning of the experiment and after 24 h of 
incubation. Untreated cells co-incubated with culture medium were 
used as a control. The cells were incubated for 42 h at 37°C, washed 
3-fold by buffer A, fixed by methanol for 10 min, dried and stained by 
crystal violet solution in 20%> ethanol for 1 h. Optical density in the 
wells containing crystal violet stained cells was determined by Multi-
scan MCC/340 spectrophotometer at 540 nm [7]. Influence of the test 
substances on proliferation of L929 cells was determined according 
to: 
Change of total cell number (%) = 
OD540 in the sample—OD540 in the control 
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0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / / S 0 0 1 4 - 5 7 9 3 ( 9 7 ) 0 0 9 9 1 - 5 
126 E. Yu. Blishchenko et al.lFEBS Letters 414 (1997) 125-128 
Influence of the test substances on proliferative rate of target cells was 
calculated as described in [8]: 
Change of proliferative rate (%) — 
OD540 in the sample—OD540 in the control 
OD540 in the control—OD540 for initial cell number 
X100% (2) 
OD540 for initial cell number was determined before beginning of the 
incubation procedure. To estimate the background absorption for 
each plate OD540 of the wells containing culture medium was deter-
mined. The reproducibility of results was tested in 5 separate experi-
ments. The results of evaluation of statistical significance of the 
obtained values and corresponding standard deviations are given in 
Fig. 3. 
3. Results 
To examine weather NKT and des-Arg-NKT are released 
by erythrocytes, human red cells were incubated in phosphate 
buffer (buffer A) for 20, 40 and 80 min at 37°C. The obtained 
supernatants were subjected to RP-HPLC separation and the 
peaks corresponding to NKT and des-Arg-NKT standards 
were isolated (Fig. 1). Determination of the amino acid se-
quences of the obtained substances showed that erythrocytes 
secrete NKT, but not des-Arg-NKT, since the peaks with 
elution parameters corresponding to des-Arg-NKT standards 
were due to dipeptide LV (peak 1) and a non-peptide com-
pound (peak 2). Thus, erythrocytes do not release detectable 
amounts of des-Arg-NKT, the NKT/ des-Arg-NKT ratio in 
erythrocytes being about 1:1. The results obtained demon-
strate the selectivity of the secretion of peptides formed inside 
erythrocytes. They also speak of the fact that hemolysis of the 
erythrocytes practically does not take place during the incu-
bation procedure. 
Fig. 2 shows the time dependence of NKT release. The 
content of NKT was estimated from the sequencing data 
and from the measurement of peak areas by means of Multy-
ChromSpectr program (version 2.67). As seen from Fig. 2, 
reliable level of NKT (about 10 pmol/ml) is detected after 
20 min of erythrocyte incubation, and after 1.5 h the content 
of the peptide increases approximately 1.5-fold. From these 
data we conclude that the peptide is secreted by the cells from 
the very beginning of incubation and is accumulated with 
relatively slow rate in the culture medium. 
7 1 3 . 1 1 n-J 
- ^ 
NKT 
des-Arg-NKT 
5 IO 15 2D 25 30 35 4Q 45 min 
19.14 MU 
Fig. 1. RP-HPLC of supernatant of primary culture of human erythrocytes. Elution zones of NKT and des-Arg-NKT are shaded. 
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Des-Arg-NKT was shown earlier to induce cytolysis of hu-
man erythroid leukemia (K562) and L929 tumor cells, NKT 
being inactive in the same conditions [4]. The test applied 
allowed to calculate the dead/total cell ratio but not the in-
fluence of the test substances on proliferation of target cells 
[9]. In this work we examined the influence of both peptides 
on growth of L929 cells. As seen from Fig. 3, both peptides 
increased significantly L929 cell number. Obtained results 
speak of ability of both peptides to stimulated proliferation 
of tumor cells. Proliferative activity of the peptides was calcu-
lated using Eq. 2: 10~6 M of NKT caused approximately 1.5-
fold increase of proliferative rate of L929 cells (56 ± 8%), while 
des-Arg-NKT showed lesser values of proliferative activity 
(37 ± 6%). The detected difference might be due to lysis of a 
restricted population of target cells by des-Arg-NKT [5]. 
Thus, NKT exhibits only proliferative activity, while its 1^1 
fragment has both growth regulatory and cytotoxic effects [5] 
in tumor cells. 
4. Discussion 
Differences in the content of NKT and des-Arg-NKT in 
tissue extracts could be due both to differences in the secretion 
rate of the peptides from the erythrocytes and to differences in 
the proteolytic activity of tissue-specific proteinases [4]. Since 
erythrocytes were shown recently to release biologically active 
hemoglobin fragments [10], we have examined the possibility 
of NKT and des-Arg-NKT secretion by these cells. 
It follows from the obtained results that the presence of 
NKT in different tissues is, at least partially, due to secretion 
of this peptide by erythrocytes. At the same time, des-Arg-
NKT might be formed from NKT by tissue proteolytic en-
zymes or released from the destroyed erythrocytes. Thus, we 
established (i) the selectivity of secretion of the peptides 
formed inside the erythrocytes, (ii) the difference in the mech-
anism of generation of hemoglobin-derived peptides in tissues. 
As soon as both NKT and des-Arg-NKT increased the 
number of L929, we cells assumed that both peptides act as 
growth factors of L929 cells, while the less values of the effect 
mediated by des-Arg-NKT were due to cytotoxic activity of 
this peptide. 
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Fig. 2. Time dependence of NKT secretion by human erythrocytes 
(concentration of the erythrocytes was 2.5X109 cells/ml). S.D. is 
represented by bars. 
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Fig. 3. Proliferative activity of NKT (light) and des-Arg-NKT 
(dark). S.D. is represented by bars. Statistically significant data 
(P<0.05) are marked as *. 
Des-Arg-NKT was shown earlier to induce several cytolytic 
processes differing in concentration parameters and DNA 
fragmentation mechanisms both in L929 and K562 cells [4]. 
The obtained results allow to suggest that L929 cell subgroups 
respond differently to the action of des-Arg-NKT, i.e. the 
peptide increases proliferation rate of the larger part of the 
cells and kills a restricted portion of the same cell population. 
The discrete maxima of cytotoxicity are explained by differ-
ences in time required for development of respective cytolytic 
process [10]. Possibly, these maxima reflect differences in the 
sensitivity of the cells passing through different cell cycle 
stages to the action of this cytotoxic peptide [11]. Since cyto-
toxicity of des-Arg-NKT is relatively low, we assume that 
only one particular stage of the cell cycle is sensitive to the 
cytotoxic action of the peptide. 
As far as the ability to induce both proliferative and cyto-
lytic/cytostatic effects (dependent on tumor line type and on 
concentration of the test substance) is a characteristic feature 
of a variety of biologically active peptides [8,12], des-Arg-
NKT might also cause effective lysis and, accordingly, de-
crease of cell number in other tumor cell lines. 
The obtained results show that both peptides might partic-
ipate in regulation of tumor cell growth. In particular, tumor 
development could be a consequence of enhanced accumula-
tion of NKT due to increased secretion of the peptide or to its 
reduced degradation rate. In any case, the effects exhibited by 
NKT and its fragment fall in line with the earlier formulated 
concept of the role of fragments of functional proteins in 
maintenance of tissue homeostasis, i.e. in regulation of pro-
liferation, differentiation and death of both normal and tumor 
cells [9]. 
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